

ASCEPT-APSA 2020 Posters

as at 2 November 2020

All poster presentations will be uploaded to the poster gallery and can be viewed at your leisure from Tuesday 17 November and throughout the virtual meeting.

Cardiovascular	
400	Raising awareness and early detection of undiagnosed atrial fibrillation through a systematic population-based screening program in Tasmania Mr Ibrahim Jatau Abubakar, University of Tasmania
401	Correlating functional studies of human bitter taste receptors (T2Rs) in humans and mice Mr Conor Bloxham, The University of Queensland
402	Pharmacological plasma cell depletion with Bortezomib does not attenuate angiotensin II-induced hypertension Ms Hericka Bruna Figueiredo Galvão, La Trobe University
403	The pro-resolving lipid mediator lipoxin A4 protects against inflammation in diabetic cardiomyopathy Ms Ting Fu, The University of Melbourne
404	Rivaroxaban for people with stage 4 chronic kidney disease and atrial fibrillation Mrs Andreea Kelso, Queensland Health, Princess Alexandra Hospital
405	Anandamide-induced vasodilatation in normotensive and hypertensive rats Ms Daria Kornienko, The University of Melbourne
406	Pravastatin targeting of myometrial artery endothelium-dependent vasodilation in preeclampsia Mr Nathan Luque, University of New South Wales
407	Deletion of orphan GPCR, GPR37L1, alters autonomic control of cardiovascular homeostasis in mice Ms Margaret Mouat, UNSW Sydney
408	Psychometric properties of self-reported medication adherence tools in cardiovascular disease: A systematic review Mr Henok Tegegn, University of New England
409	The nitroxyl donor Angeli's salt circumvents nitric oxide resistance in the insulin-resistant diabetic myocardium Ms Anida Velagic, Monash University
410	Spatial reference memory impairment is augmented in hypertensive mice following stroke Dr David Wong Zhang, La Trobe University
Clinical Pharmacology	
411	Efficacy and safety of metaraminol infusions in critical care: A systematic review and meta-analysis Ms Arwa Abu Sardaneh, Royal Prince Alfred Hospital
412	The association between menopausal status and remission in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs Mrs Dala Daraghme, University of South Australia
413	Chronic polypharmacy and increasing Drug Burden Index (DBI) impair cognitive function in aged mice Ms Gizem Gemikonakli, The University of Sydney
414	How are antibiotics prescribed for open reduction internal fixation procedures? Ms Sarah Hassan, RMIT University
415	Perceptions of Gout in East Asia Miss Maria Hernandez Castellanos, University of New South Wales
416	Bayesian approach shows lack of difference between Aboriginal and Caucasian kidney transplant recipients in mycophenolic and tacrolimus pharmacokinetics Prof Nick Holford, University of Auckland
417	Development and validation of a Liquid Chromatography tandem Mass Spectrometry (LCMSMS) assay investigating pharmacokinetics of phosphatidylethanol Prof David Joyce, University of Western Australia

Clinical Pharmacology <i>continued</i>	
418	Applications of using drug monitoring for Ivacaftor and Tezacaftor treatment response in Cystic Fibrosis Dr Elena Schneider-Futschik, The University of Melbourne
419	A step forward in patient safety – understanding barriers to correct intravenous medication administrations Miss Catriona Shen, University of New South Wales
420	Predictive performance of population pharmacokinetic models for tacrolimus in lung transplant recipients Ms Rani Singh, University of New South Wales
421	Adverse drug reactions presenting to acute medical admissions: A pilot prevalence study Mr Jules Thompson, Cardiff University
422	Application of physiologically-based pharmacokinetic modelling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukaemia Mrs Josephine Touma, The University of Sydney
423	VTE prophylaxis in orthopaedic surgery – patient individualised or ‘one-dose-fits-all’? Mr Nameer van Oosterom, The University of Queensland; Princess Alexandra Hospital
Drug Discovery	
424	A common allosteric mechanism for stabilising agonist ligand binding at GPCRs Mr Wessel Burger, Monash University
425	Calcium communication in an in vitro model of breast cancer brain metastases Silke Chalmers, The University of Queensland
426	Biased negative allosteric modulators for the calcium-sensing receptor have differential bronchodilator and bronchoprotective effects in mouse precision cut lung slices Miss Jiayin Diao, Monash University
427	The effect of single nucleotide polymorphisms on sweet taste receptor expression and cell surface trafficking Miss Jennifer Grant, University of New South Wales
428	Expanding the peptide synthesis toolkit to produce bicyclic peptide mimetics for drug discovery Ms QingQing Lin, The University of Melbourne
429	Characterisation of the G protein coupling profiles of PAC1 receptor splice isoforms Miss Jessica Lu, Monash University
430	Understanding GPCR signal compartmentalisation using optogenetic methods Miss Chantel Mastos, Monash University
431	Differential G protein activation kinetics may underpin the beneficial aspects of clinically trialled adenosine A1 receptor atypical agonists Ms Samantha McNeill, Monash University
432	GPCR-CoINPocket2.0: Refining the prediction of liganded pharmacological neighbours of unliganded orphan GPCRs Mr Sean So, University of New South Wales
Drug Disposition and Response	
433	Evaluation of meropenem-tobramycin combination regimens against clinical hypermutable <i>Pseudomonas aeruginosa</i> via mechanism-based modelling and the dynamic hollow fibre infection model Ms Akosua Agyeman, Monash University
434	Synergistic ceftazidime and tobramycin combinations for clinical hypermutable <i>Pseudomonas aeruginosa</i> isolates; an innovative dosing approach to enhance bacterial killing and mitigate resistance in a dynamic biofilm model Ms Hajira Bilal, Monash University
435	Effect of high Drug Burden Index polypharmacy on physical function and daily activities: Male and female, young and old mice Dr John Mach, The University of Sydney
436	The role of UGT enzymes as novel modulators of lipid biosynthesis and SREBP signalling in breast cancer Mr Jai Meyers, Flinders University

Education	
437	Survey of how and why students use resources in a pharmacology course Dr Sheila Doggrell, Queensland University of Technology
438	An examination of extemporaneous compounding skills, knowledge and confidence progression from undergraduate to practice: A pharmacy education perspective Mr Quang Hung Duong, Monash University
439	Communicating health risks of nicotine vaping products: A review of message feature, and source on harm perception and behavioural intentions Mr Daniel Erku, The University of Queensland
440	Integrating virtual simulation (MyDispense) for teaching comprehensive care pharmacy curriculum Dr Betty Exintaris, Monash University
441	Implementing and evaluating a course in professional ethics for the undergraduate pharmacy curriculum in Jordan Ms Leen Fino, The University of Sydney
442	Development and delivery of a pharmacology fundamental unit for first-year undergraduate students Dr Marina Junqueira Santiago, Macquarie University
443	Practising teamwork begins in the classroom: Tools to evaluate teamwork behaviour in small group activities Dr Nilushi Karunaratne, Monash University
444	Prevalence and predictors of health information overload in patients with a chronic condition: A national survey Mrs Israa Khaleel, University of Tasmania
445	Students in the driving seat – online delivery of real time interactive practical classes Dr Makhala Khammy, The University of Melbourne
446	Using PollEverywhere and content chunking during remote delivery in an undergraduate course Dr Iris Lim, Bond University
447	iiBalls: An updated and expanded iris simulation to teach autonomic pharmacology and diagnostic ocular drugs Dr Graham Mackay, The University of Melbourne
448	Exploring transitional challenges in preparing pharmacy students for practice Miss Aisling McEvoy, Monash University
449	Improving communication with patients with regards to the risk of SGLT2 inhibitor-associated diabetic ketoacidosis Dr Tamara Milder, St Vincent's Hospital
450	COVID-19 and emergency online delivery: What worked for a pharmacology course? Dr Suong Ngo, The University of Adelaide
451	Type 2 diabetes – a risk of underdiagnosis in those with risk factors for diabetes Ms Emily Pickering, The University of Queensland
452	Meat in the sandwich? Effect of the pharmacy residency program on pharmacy educators Mr Chih Yuan (Jason) Wang, The University of Queensland
Inflammation/respiratory	
453	The FFA4 agonist TUG891 relaxes mouse airways by inhibiting calcium oscillations but not sensitivity in precision cut lung slices Mr Liam Allan, Monash University
454	Ebselen prevents cigarette smoke-induced endothelial dysfunction in viral-induced exacerbations of COPD Mr Kurt Brassington, RMIT University
455	Differential activation of human MRGPRX2 by polymyxins and related antibiotics Miss Jie Ding, The University of Melbourne
456	The effect of substance P and its common metabolites on MRGPRX2 activation in human mast cells Miss Lin Hsin, The University of Melbourne
457	Cigarette smoking does not worsen skeletal muscle contractile function or loss caused by acute viral infection in mice Mr Kevin Mou, RMIT University
458	Expression profiling of specialised pro-resolving receptors in human peripheral blood mononuclear cells (PBMCs) and polymorphonuclear leukocytes (PMNs) Miss Julia Park, Monash University
459	Characterisation of chemokine-dependent signalling in monocytes via chemokine GPCRs CCR1 and CCR2 Miss Rina Pokhrel, Monash University

Neuro- and Behavioural Pharmacology	
460	Involvement of P-glycoprotein (ABCB1) in the export of amyloid-beta from the Alzheimer's brain Miss Amanda Chai, The University of Sydney
461	Utilizing mini-G protein biosensors and BRET to profile orexin receptor pharmacology Miss Natasha Dale, Harry Perkins Institute of Medical Research
462	Ivacaftor, a cystic fibrosis modulator drug, in pregnancy and lactation: Entry into the developing brain and lung Ms Fiona Qiu, The University of Melbourne
463	Can monitoring clozapine levels reduce the occurrence of peripheral ADRs? Ms Madeleine Tan, The University of Queensland
464	Entry of valproate and lamotrigine into the developing brain Mr Samuel Toll, The University of Melbourne
465	Male-female differences in the effects of age on mouse activities of daily living measured using an automated behavioural classification system Ms Trang Tran, The University of Sydney
Pharmaceutical Science	
466	Self-nanomicellizing solid dispersion of USA612: Solubility improvement Ms Fatima Abid, University of South Australia
467	Does co-administering whole and crushed paracetamol with Gloup alter drug dissolution profile in vitro? Ms Marwa Abu Malouh, The University of Queensland
468	Co-amorphous kanamycin-amino acid spray-dried inhalable particles: The influence of feed concentration in achieving high aerosolization Mr Bishal Adhikari, University of Otago
469	Characterization of Novel Inulin hydrogels loaded with 5-fluorouracil for colon delivery Dr Franklin Afinjuomo, University of South Australia
470	Glycine-Proline-Glutamate loaded bi ligand niosomal delivery system interactions on Cell Models Mr Murad Al Gailani, University of Auckland
471	Hand sanitizer during COVID-19 in New Zealand: A response to the community by the School of Pharmacy, University of Otago Dr Shyamal Das, University of Otago
472	Novel functionalized mesoporous silica nanoparticles targeting estrogen receptor over-regulated breast cancer Ms Candace Day, University of South Australia
473	A novel rat cervical lymph cannulation method to evaluate the lymphatic clearance of therapeutics from the brain Ms Thu Hoang, Monash University
474	Triple negative breast cancer: Screening for the invasion amplifying cAMP-calcium feedforward loop mechanism Mr Terrance Lam, Monash University
475	An effective HPTLC method for quality standardisation of Australian propolis Dr George Li, Western Sydney University
476	The expression and function of fatty acid-binding proteins in microglia: A potential role in the uptake of docosahexaenoic acid? Ms Yi Ling Low, Monash University
477	Copper complexes modulate the expression and function of P-glycoprotein at the blood-brain barrier Mr Jae Pyun, Monash University
478	Method development and validation for determination of sucralfate in marketed tablets by HPLC-ELSD Ms May Song, University of South Australia
479	Determination of residual N,N-dimethylformamide in drug eluting pharmaceutical formulations Ms Souha Youssef, University of South Australia

Pharmacoepidemiology	
480	Pharmacoepidemiology of metaraminol in critically ill patients with shock Ms Arwa Abu Sardaneh, Royal Prince Alfred Hospital
481	Tools to evaluate medication management for caregivers of people with dementia: a systematic review Miss Melissa Gench, The University of Sydney
482	Vasopressor dose equivalence: A scoping review and suggested formula Miss Shruti Goradia, The University of Sydney
483	The prevalence of opioid analgesic use in people with chronic non-cancer pain: Systematic review and meta-analysis Dr Stephanie Mathieson, The University of Sydney
484	Duration of postoperative opioid use after hip or knee surgery: a systematic review and meta-analysis Miss Xinyi Wang, The University of Sydney
Pharmacogenomics	
485	Effect of CYP2B6 516G>T on Plasma Efavirenz and 8OH-Efavirenz Concentrations in Papua New Guinea HIV patients Miss Helena Van Schalkwyk, The University of Adelaide
Pharmacy Practice	
486	Current pharmacological and non-pharmacological interventions for illicit drug-induced presentations in emergency departments: A literature review Ms Ruby Tszwai Au, University of South Australia
487	Development and validation of explicit criteria for identification of potentially inappropriate prescribing for people with type 2 diabetes mellitus Mr Mohammed Ayalew, University of New England
488	Exploring the knowledge and attitudes of clients living with mental health conditions towards their medications and their healthcare providers Ms Tien Bui, University of South Australia
489	Medication safety during ICU care transfers with an electronic medication management system Ms Racha Dabliz, The University of Sydney
490	Exploring pharmacy ethics in developing countries – a scoping review Ms Leen Fino, The University of Sydney
491	Pharmacist's and physiotherapist's perspectives about sports pharmacy Mrs Alison Hooper, University of Newcastle
492	The psychosocial and work related impacts of the COVID-19 pandemic on Australian Pharmacists Mrs Karlee Johnston, Australian National University
493	Deprescribing opioid analgesics: An overview of systematic reviews Ms Aili Langford, The University of Sydney
494	Extended roles in Aotearoa New Zealand community pharmacy: The views of service users Dr Caroline Morris, University of Otago
495	Interventions at hospital discharge to guide caregivers in medication management for people living with dementia: A systematic review Dr Mouna Sawan, The University of Sydney
496	Role of medication beliefs on medication adherence in hypertensive Middle Eastern refugees and migrants in Australia Mrs Wejdan Shahin, Rmit University
497	A pilot pharmacist health coaching trial investigating changes to modifiable health behaviours Ms Harjit Singh, RMIT University
498	Exploring contributing factors of acute psychological impact in community pharmacists due to COVID-19 pandemic Dr Vijay Suppiah, University of South Australia
499	A qualitative study exploring barriers to and facilitators of medication adherence in Ethiopia: Hospital pharmacists' perspectives Mr Henok Tegegn, University of New England
500	Implementation of a customised automation tool to optimise pharmacy practice Mr William Tumusiime, Ipswich Hospital
501	The impact of QHMAC LAM restrictions on the prescription qty of oxycodone prescribed on discharge Mr William Tumusiime, Ipswich Hospital
502	An audit of the appropriateness of antipsychotic prescribing for cognitive impairment Mr William Tumusiime, Ipswich Hospital
503	Virtual Renovation of the Medication and Pharmacist Engagement Clinic (MAPEC) Mr William Tumusiime, Ipswich Hospital

Toxicology	
504	Evaluation of efavirenz and 8-OH-EFV exposure and the occurrence of drug-induced side effects in Papua New Guinea HIV/AIDS patients Ms Natalia Bordin Andriqueti, The University of Adelaide
505	Cefepime-induced neurotoxicity: Identifying the toxicity threshold Ms Cindy Lau, St Vincent's Hospital
506	Green tea extract and its metabolites induce biochemical changes linked to hepatotoxicity in HepG2 cells Dr Garth Maker, Murdoch University
507	Exploring the TRAIL of doxorubicin-induced cardiotoxicity Ms Michelle Sims, University of Adelaide
508	Ascending Jacob's Ladder of Density Functional Approximations for in silico toxicological modelling Mr John Spicer, The University of Sydney

Thank you to our sponsors

Principal sponsor

Bb Bellberry Limited
supporting research and ethics

Platinum sponsors



**BRITISH
PHARMACOLOGICAL
SOCIETY**



Gold sponsors

A|F|T *pharmaceuticals*
Working to improve your health



**UNSW
SYDNEY**



Silver sponsors

PKPDRX

douglas
improving lives

evolve
Better care. Better decision-making. Better use of resources.

Bronze sponsors

 **pharmaceuticals**
an Open Access Journal by MDPI

**APAC
SCIENTIFIC**



BMG LABTECH
The Microplate Reader Company

